AREDS Studies


The Age-Related Eye Disease Study, also known as AREDS, was a major landmark clinical study sponsored by the National Eye Institute, one of the federal government's National Institutes of Health. AREDS2 was a second major clinical study sponsored by the National Eye Institute.


The 2013 Age-Related Eye Disease Study 2


AREDS2 was a second major clinical study sponsored by the National Eye Institute. The primary goal of AREDS2 was to determine if adding other nutrients to the original AREDS antioxidant and zinc formula would further reduce the risk of developing advanced Age-related Macular Degeneration (AMD). 1,2

AREDS2 Study Highlights:


  • Independent 5-year clinical study

  • 4,200 participants with moderate to advanced Age-related Macular Degeneration (AMD)

  • Examined benefits of adding lutein & zeaxanthin and omega-3 fatty acids to original AREDS formula

Based on the results from the AREDS2 study, the NEI has proposed a modification to the original AREDS supplement formula as follows:


  • Removing beta-carotene (due to concerns regarding the increased risk of lung cancer in current or former smokers)

  • Adding 10 mg lutein and 2 mg zeaxanthin (per day)

The complete updated AREDS formula based on the results of the AREDS2 study is summarized here.






To hear a leading retina specialist discuss the AREDS2 studies, click here.

PreserVision AREDS 2 Formula exactly matches the levels of clinically proven nutrients recommended by the National Eye Institute based on the AREDS2 study.*

For more information from the National Eye Institute on the 2001 Age-Related Eye Disease Study (AREDS) and the 2013 AREDS2 study, Click Here >>.

The 2001 Age-Related Eye Disease Study

AREDS Study Highlights:

  • Independent 5-year clinical study

  • 3,600 participants with varying stages of Age-related Macular Degeneration (AMD) Age-related Macular Degeneration (AMD)

  • Proved that taking a supplement with 80mg zinc and antioxidants (vitamins C&E and beta-carotene) reduced the risk of AMD progression by 25% and vision loss by 19% in people with moderate to advanced AMD *2

  • Resulted in “AREDS formula” vitamins becoming recognized as standard of care by eye doctors for people with moderate to advanced AMD*

The supplement tested and clinically proven in the AREDS study was the original Bausch & Lomb PreserVision Eye Vitamin AREDS Formula.*

It’s important to know that the levels of antioxidants and zinc as studied in AREDS are well above what is generally attainable through even a well-balanced diet.  It is also not provided by standard daily multivitamins or even regular eye vitamins.

To hear Dr. Cooney discuss the AREDS studies, click here >>.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

References

1. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA. 2013 May 15; 309(19):2005-15. AREDS2 is a registered trademark of the United States Department of Health and Human Services (HHS)

2. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with Vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS Report No. 8. Arch Ophthalmol. 2001:119(10):1417-1436.

3. National Eye Institute website: http://www.nei.nih.gov/areds2/ Accessed October 2013.